Buprenorphine/naloxone

Ibogaine By David Dardashti Analyzes Connections Between Physical and Emotional Pain

Retrieved on: 
Monday, January 15, 2024
Hydrocodone, Oxycodone, Fentanyl, Physical fitness, Communication, Opioid, Chronic pain, Ibogaine, Pain, Methadone, Buprenorphine/naloxone, Research, Brain, Nursing

While opiates are commonly used to treat physical pain, they have been found to have a significant impact on emotional pain as well.

Key Points: 
  • While opiates are commonly used to treat physical pain, they have been found to have a significant impact on emotional pain as well.
  • Research suggests that opiates enhance the production of opiate receptors, creating interconnected pathways that regulate both physical and emotional pain.
  • These drugs create interconnected pathways that regulate both emotional and physical pain, providing relief to individuals struggling with opioid addiction.
  • This not only helps individuals recover without having to undergo physical and emotional discomfort, but also stabilizes the brain and body, improving communication between physical and emotional pain.

AltaPointe's Behavioral Health Crisis Center Offers Innovative Approach to Fentanyl Addiction Treatment Using Ketamine in Combination with Buprenorphine

Retrieved on: 
Thursday, November 9, 2023
BHCC, Buprenorphine, Ketamine, Heroin, Patient, Fentanyl, Chronic pain, Pharmaceutical industry, Cereal, Buprenorphine/naloxone

MOBILE, Ala., Nov. 8, 2023 /PRNewswire-PRWeb/ -- In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront. AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.

Key Points: 
  • In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront.
  • AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.
  • MOBILE, Ala., Nov. 8, 2023 /PRNewswire-PRWeb/ -- In the ongoing battle against the fentanyl epidemic, a promising new approach has emerged and AltaPointe Health is at the forefront.
  • AltaPointe's Behavioral Health Crisis Center (BHCC) has started offering the use of ketamine to help transition a patient from fentanyl to buprenorphine (often referred to by the common brand name Suboxone), a proven addiction-treatment medicine.

Wexler Boley & Elgersma LLP, Miller Law LLC, Hilliard Shadowen LLP, Motley Rice LLC, and Spector Roseman & Kodroff P.C. Announce a $30 Million Class Action Settlement for Those Who May Have Purchased or Provided Reimbursement for the Drug Suboxone or Gene

Retrieved on: 
Monday, August 28, 2023
AK, AB, ME, Vexatious litigation, Payment card interchange fee and merchant discount antitrust litigation, CO, District court, Notice, Court, Hearing, RI, OR, Market Street, PR, Dubrovka, Dubrovsky Settlement Administrative Okrug, Dubrovsky District, Bryansk Oblast, Buprenorphine, Clerk, FORM, Letter, Reckitt, Lawsuit, Fairness, HI, Settlement, Court order, OK, Summons, Insurance, Buprenorphine/naloxone, Class, MD, Indivior

The Court has preliminarily approved a proposed settlement between the Class and Indivior (the "Settlement").

Key Points: 
  • The Court has preliminarily approved a proposed settlement between the Class and Indivior (the "Settlement").
  • The proposed Settlement will provide for the payment of $30 million (the "Settlement Fund") to resolve the Class claims against Indivior.
  • The deadlines contained in this Notice may be amended by Court Order, so check the Settlement website for any updates.
  • SOURCE Wexler Boley & Elgersma LLP, Miller Law LLC, Hilliard Shadowen LLP, Motley Rice LLC, and Spector Roseman & Kodroff P.C.

‘They weren’t there when I needed them’: we asked former prisoners what happens when support services fail

Retrieved on: 
Monday, July 24, 2023
People, Well, Buprenorphine/naloxone, Department, Prison, Housing, Parole, NUAA, Friends, Pharmacy, Prisoner, Trust, Woman, Substance dependence, Rehabilitation, Public housing, History, Imprisonment, Heroin, Switchmen's Mutual Aid Association, Philosophy, Man, AIDS, Work, Canadian International Council, Time, Risk, Drug policy, Empathy, Substance use disorder, Health, Mental health, Psychedelic literature, John Hodgman, Drug, Online shopping, Residential care, Nursing, Creative industries, Maintenance (technical), Centrelink

Like you know transitioning to housing, even help with you know finding work and that, but […] none of those promises were met.

Key Points: 
  • Like you know transitioning to housing, even help with you know finding work and that, but […] none of those promises were met.
  • Like you know transitioning to housing, even help with you know finding work and that, but […] none of those promises were met.
  • Getting this kind of pre- and post-release support can drastically reduce the risk of the person re-offending.

System failure


    In 2019‑20, 46% of prisoners released in 2017-18 had returned to prison within two years. People who inject drugs are disproportionately more likely to return to prison. This suggests a systemic failure; something is going wrong in the way we provide services to this group of people. For this analysis, “service providers” include actors such as:
    • For example, when Jidah got out of prison, he needed crucial medication for his opioid dependence.
    • And I was that frustrated that it caused me to relapse and get back on the heroin.
    • And I was that frustrated that it caused me to relapse and get back on the heroin.
    • Khish told us he was given some support in getting set up for post-prison life but the help was limited.

Trust is key

    • Being able to trust a service provider is crucial and can enable a smoother transition to community.
    • Ben, however, didn’t find his parole officer “useful”, saying:
      They’re not really there to help you.
    • They’re there to watch over you, but they say they can help.

Getting the right support can be ‘life-changing’

    • Under this new philosophy, Maine’s prisons focus on rehabilitation and growing respect between correctional officers and people who are incarcerated.
    • It can help reduce the chances the prison system is simply reproducing disadvantage and replicating the problems it is ostensibly supposed to solve.
    • If you or someone you know needs help with exiting prison, you can find a list of resources here.
    • The NSW Users and AIDS Association (NUAA) PeerLine on 1800 644 413 may also be helpful.

REVERIE MIND LAUNCHES "URGENT" PROGRAM TO PROVIDE SUBOXONE THERAPY TO ADULTS AND ADOLESCENTS IN NEED

Retrieved on: 
Thursday, March 30, 2023
Buprenorphine/naloxone, Ketamine, Opioid use disorder, Patient, Medical director, Mental health, FAPA, Pharmaceutical industry

Our URGENT program is designed to provide care to patients who are in need of Suboxone Therapy for opioid use disorder.

Key Points: 
  • Our URGENT program is designed to provide care to patients who are in need of Suboxone Therapy for opioid use disorder.
  • "The launch and formation of the URGENT program is designed to provide immediate aid to patients who are in need of addiction therapy.
  • Our URGENT program is led by our Medical Director, Dr. Lauro Amezcua-Patino MD, FAPA which had the following to say, "Reverie Mind is the premiere provider of psychedelic research, ketamine, and suboxone therapy in Arizona.
  • To learn more about Reverie Mind and our URGENT program, please call us at 1-855-738-6463 or visit us at www.reveriemind.com

Global Naloxone Market Report 2022 to 2030: Parenteral Segment Dominated the Formulation Market - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023
Health, Pharmaceutical, Heroin, Drug, Drug overdose, Opioid overdose, Oxycodone, Buprenorphine, Fentanyl, Incidence, Morphine, Death, Growth, Opioid, Injection, Prevalence, Hydrocodone, Hospital, Speciality chemicals, Marketing, Renewable energy, Naloxone, Buprenorphine/naloxone

The global naloxone market is expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030.

Key Points: 
  • The global naloxone market is expected to grow at a CAGR of 10.1% during the forecast period of 2022-2030.
  • The increasing prevalence of opioid overdoses is expected to drive the growth of the naloxone market.
  • An increasing incidence of opioid drug abuse in both the developed and developing worlds remains the key driver for the market growth of the naloxone market.
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Naloxone market worldwide?

Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims

Retrieved on: 
Monday, October 24, 2022
LinkedIn, U.S. Securities and Exchange Commission, Sale, Risk, Therapy, Growth, Buprenorphine/naloxone, Clobazam, Lennox–Gastaut syndrome, Annual report, NASDAQ, Drug development, Judgement, Court, Allergy, Seizure, Adrenaline, Technology, Private Securities Litigation Reform Act, Anaphylaxis, Company, Marketing, Industry, District court, Diazepam, Legislation, Health, Safety, CNS, GLOBE, Intellectual property, Failure, FDA, COVID-19, Central nervous system, Compliance, Pharmaceutical industry

This judgment is another step forward in improving our business, said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • This judgment is another step forward in improving our business, said Daniel Barber, Chief Executive Officer of Aquestive.
  • Aquestive Therapeutics, Inc.(NASDAQ: AQST) is a pharmaceutical company advancing current standards of care to solve patients problems through simplifying complex delivery methods.
  • We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies.
  • PharmFilm, Sympazan and the Aquestive logo are registered trademarks ofAquestive Therapeutics, Inc.

Groups Recover Together Expands Access to Transitional Care and Substance Use Disorder Treatment for Criminal Justice-involved Hoosiers

Retrieved on: 
Tuesday, October 25, 2022
Public Policy, Government, Telecommunications, Public Relations, Investor Relations, General Health, Health, Healthcare Reform, Communications, Technology, LinkedIn, Insurance, Medicaid, Office of Federal Contract Compliance Programs, Transport, Population, Opioid use disorder, MAT, Prison, YouTube, National Academy of Sciences, Orientation, Iowa Department of Corrections, Crime, John Hodgman, Program, Drug, Mortality, Recidivism, Technology, MD, Department, Science, Buprenorphine, Indiana Department of Environmental Management, Imprisonment, Trauma, CEO, Indiana Department of Correction, Opioid, National academy, Hoosier, Pharmaceutical industry, Risk management, Health insurance, Group, Buprenorphine/naloxone, Facebook

Groups Recover Together , the nationwide leader in value-based care for opioid addiction treatment, has announced a collaboration with the Indiana Department of Corrections to coordinate transitional Opioid Use Disorder treatment for releasing citizens across the state.

Key Points: 
  • Groups Recover Together , the nationwide leader in value-based care for opioid addiction treatment, has announced a collaboration with the Indiana Department of Corrections to coordinate transitional Opioid Use Disorder treatment for releasing citizens across the state.
  • In fact, 85% of the prison population has an active substance use disorder or were incarcerated for a crime involving drugs or drug use.
  • As part of this collaboration, Indiana DOC Transitional Care members identify releasing citizens with Opioid Use Disorder and help them schedule a rapid intake with Groups.
  • This includes overcoming barriers to treatment that individuals may face such as lack of transportation or limited access to technology.

Bicycle Health and Evernorth Team Up to Expand Access to Virtual Opioid Use Disorder Treatment

Retrieved on: 
Thursday, August 25, 2022
Office of Inspector General, U.S. Department of Health and Human Services, OIG, CEO, Program, Opioid use disorder, MAT, Conditional sentence, GLOBE, Leadership, News, OUD, HHS, History of the Office of the Inspector General of the United States Army, Patient, Buprenorphine/naloxone, Â, Health insurance, Cigna

Bicycle Healths virtual care model dramatically increases access to OUD treatment which is largely inaccessible in an in-person setting.

Key Points: 
  • Bicycle Healths virtual care model dramatically increases access to OUD treatment which is largely inaccessible in an in-person setting.
  • ( source )
    Through Bicycle Health, customers will have access to behavioral health clinicians who can help develop a personalized care plan, including a prescription to Buprenorphine/Naloxone (Suboxone), if appropriate.
  • Opioid use disorder is highly stigmatized in the US, which directly contributes to 90 percent of people with the disorder not pursuing treatment, said Ankit Gupta, CEO and founder of Bicycle Health.
  • Bicycle Health offers confidential evidence-based virtual care for opioid use disorder , from the comfort of your home.

Cerebral Expands Opioid Use Disorder Treatment Program to Colorado, Washington

Retrieved on: 
Thursday, May 26, 2022
General Health, Pharmaceutical, Health, Mental Health, Insomnia, Patient, Insurance, Health, Cerebral, Privacy, Bipolar disorder, Depression, Opioid, Buprenorphine/naloxone, ADHD, Plague, Program, Anxiety, United States drug overdose death rates and totals over time, Diagnosis, Pharmaceutical industry, Residential care, Health insurance, Pew

Cerebral began offering treatment for opioid use disorder -- aimed at increasing access to care and improving the health of people suffering from opioid addiction -- in Florida on March 8. The company plans to continue to expand to additional states.

Key Points: 
  • Cerebral Inc , the leading provider of online mental health services, today announced the expansion of its virtual opioid use disorder treatment program to include patients in Colorado and Washington state.
  • Cerebral began offering treatment for opioid use disorder -- aimed at increasing access to care and improving the health of people suffering from opioid addiction -- in Florida on March 8.
  • However, 82 percent of Americans suffering from opioid use disorder are still not receiving the lifesaving medication they need, according to Pew .
  • Cerebral recognizes the need for holistic treatment, as 43 percent of those struggling with opioid addiction also have a co-occurring diagnosis or symptoms of mental health disorders.